DK2032607T3 - Proteolytisk spalteligt fusionsprotein omfattende en blodkoaguleringsfaktor - Google Patents

Proteolytisk spalteligt fusionsprotein omfattende en blodkoaguleringsfaktor

Info

Publication number
DK2032607T3
DK2032607T3 DK07726010.7T DK07726010T DK2032607T3 DK 2032607 T3 DK2032607 T3 DK 2032607T3 DK 07726010 T DK07726010 T DK 07726010T DK 2032607 T3 DK2032607 T3 DK 2032607T3
Authority
DK
Denmark
Prior art keywords
fusion protein
blood coagulation
coagulation factor
cleavable fusion
proteolytic cleavable
Prior art date
Application number
DK07726010.7T
Other languages
English (en)
Other versions
DK2032607T4 (da
Inventor
Hubert Metzner
Thomas Weimer
Stefan Schulte
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37450975&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2032607(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Priority claimed from PCT/EP2007/005246 external-priority patent/WO2007144173A1/en
Publication of DK2032607T3 publication Critical patent/DK2032607T3/da
Application granted granted Critical
Publication of DK2032607T4 publication Critical patent/DK2032607T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07726010.7T 2006-06-14 2007-06-14 Proteolytisk spalteligt fusionsprotein omfattende en blodkoagulerings-faktor DK2032607T4 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012262A EP1867660A1 (en) 2006-06-14 2006-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor
US81962006P 2006-07-11 2006-07-11
PCT/EP2007/005246 WO2007144173A1 (en) 2006-06-14 2007-06-14 Proteolytically cleavable fusion protein comprising a blood coagulation factor

Publications (2)

Publication Number Publication Date
DK2032607T3 true DK2032607T3 (da) 2014-04-14
DK2032607T4 DK2032607T4 (da) 2017-05-15

Family

ID=37450975

Family Applications (2)

Application Number Title Priority Date Filing Date
DK07726010.7T DK2032607T4 (da) 2006-06-14 2007-06-14 Proteolytisk spalteligt fusionsprotein omfattende en blodkoagulerings-faktor
DK19162362.8T DK3564267T3 (da) 2006-06-14 2007-06-14 Proteolytisk, spaltbar fusionsprotein med høj molær specifik aktivitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19162362.8T DK3564267T3 (da) 2006-06-14 2007-06-14 Proteolytisk, spaltbar fusionsprotein med høj molær specifik aktivitet

Country Status (5)

Country Link
US (1) US20090042787A1 (da)
EP (3) EP1867660A1 (da)
DK (2) DK2032607T4 (da)
ES (2) ES2729426T3 (da)
PL (1) PL3564267T3 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
DE602007007923D1 (de) * 2006-04-11 2010-09-02 Csl Behring Gmbh Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
US7939632B2 (en) * 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
US20100268055A1 (en) * 2007-07-19 2010-10-21 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self-Anchoring MEMS Intrafascicular Neural Electrode
PL2291523T3 (pl) * 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) * 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
JP2013517782A (ja) * 2010-01-28 2013-05-20 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 因子ｖｉｉ融合ポリペプチド
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
KR101853405B1 (ko) 2010-10-20 2018-05-02 주식회사 티움바이오 인자 ｉｘ 활성을 갖는 융합 단백질
CN104271150A (zh) * 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 嵌合因子viii多肽及其用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
JP6256882B2 (ja) 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途
ES2761730T3 (es) 2013-01-31 2020-05-20 Pfizer Composiciones y procedimientos para contrarrestar la inhibición del factor Xa
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3063170A4 (en) * 2013-11-01 2017-06-28 The Children's Hospital of Philadelphia Compositions and methods for increasing the half-life of factor xa
EP3068891A1 (en) * 2013-11-13 2016-09-21 Aequus Biopharma Inc. Engineered glycoproteins and uses thereof
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
US10676731B2 (en) 2014-08-19 2020-06-09 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor IX function
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
KR102440820B1 (ko) * 2015-09-08 2022-09-05 테리피온, 인크. ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
AU2019271148B9 (en) 2018-05-14 2025-05-29 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
PL3793588T3 (pl) 2018-05-18 2025-09-01 Bioverativ Therapeutics Inc. Sposoby leczenia hemofilii a
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
MX2022005666A (es) 2019-11-14 2022-10-07 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3182800A1 (en) 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8927722D0 (en) 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
DE69519929T2 (de) * 1994-07-11 2001-05-23 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen für die spezifische koagulation von tumorgefässen
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001275897A1 (en) 2000-07-12 2002-01-21 Immunex Corporation Improvement of cell culture performance
ES2322945T5 (es) 2001-12-21 2012-10-17 Immunex Corporation Métodos para purficación de proteína
CN101044154A (zh) 2002-02-14 2007-09-26 威廉·J·鲁特 治疗宿主中切割的嵌合分子
US8809504B2 (en) * 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
EP1444986A1 (en) * 2003-02-07 2004-08-11 Aventis Behring GmbH Pharmaceutical preparation for the improved treatment of blood-clotting disorders
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
PL2298347T3 (pl) * 2003-05-06 2016-03-31 Bioverativ Therapeutics Inc Białka chimeryczne czynnika krzepnięcia do leczenia zaburzenia hemostazy
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life

Also Published As

Publication number Publication date
ES2468558T3 (es) 2014-06-16
US20090042787A1 (en) 2009-02-12
EP2256135A1 (en) 2010-12-01
PL3564267T3 (pl) 2021-10-11
DK3564267T3 (da) 2021-05-31
EP3564267B1 (en) 2021-03-17
ES2729426T3 (es) 2019-11-04
ES2468558T5 (es) 2017-07-18
EP3564267A1 (en) 2019-11-06
DK2032607T4 (da) 2017-05-15
EP1867660A1 (en) 2007-12-19
EP2256135B1 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
DK2032607T3 (da) Proteolytisk spalteligt fusionsprotein omfattende en blodkoaguleringsfaktor
DK3896090T3 (da) Proteolytisk spalteligt fusionsprotein omfattende en blodkoagutionsfaktor
EP2068905A4 (en) ALBUM INFUSION PROTEINS
DK2046826T3 (da) Exendin-fusionsproteiner
DE602005023247D1 (de) Bipolares elektrochirurgisches Instrument mit Gelenk
DE602005024846D1 (de) Blutdialysator
EP2172198A4 (en) P27 PROTEIN INDUKTOR
DE102004026598A8 (de) Hochfrequenzchirurgiegerät
EP2046367A4 (en) ALBUM INFUSION PROTEINS
EP1863558A4 (en) ELECTRO-SURGICAL CANNULA
BRPI0815368A2 (pt) "proteinas c-fms humanas a antigeno"
DE602005020157D1 (de) Blutreinigungsgerät
DE602005024162D1 (de) Blutreinigungsgerät
DE602005017840D1 (de) Blutdruckmonitor
DE602005018991D1 (de) Elektrochirurgisches Handstück
ATE412389T1 (de) Chirurgisches system mit integrierten pneumatischen übergangsstücken
ITPD20040252A1 (it) Irrigatore chirurgico
ATE537183T1 (de) Hiv-fusionshemmerpeptide mit verbesserten biologischen eigenschaften
ATE481625T1 (de) Chirurgisches system mit nicht-invasivem durchflusssensor
ITBO20040642A1 (it) Giunto vascolare
DE602005014425D1 (de) Fussschalter mit Ausgabesystem
DE602006001598D1 (de) Spitze zur Phakoemulsifikation
DK1809660T3 (da) Thymus-specifikt protein
EP1793137A4 (en) UNIVERSAL JOINT
DE602006007833D1 (de) Blutdrucksenkende proteinhydrolysate